Bath & Body Works Inc. announced on Wednesday, Feb. 23, that Andrew Meslow is stepping down as the company’s chief executive officer. It was noted that the executive is leaving less than a year after BBW became an independent public firm.
As per Reuters, Meslow decided to vacate his post at Bath & Body Works for health reasons which was not explained further. He started to serve as the company’s CEO in early 2020, taking over the reins from Leslie Wexner, the L Brands founder.
Prior to his assignment as the new chief, he has held several positions at Bath & Body Works throughout his almost 20 years of employment there. Meslow will also be making his exit as part of the company’s board.
To fill up the seat vacated by the outgoing CEO, Bath & Body Works appointed Sarah Nash as interim chief. Later, the company will assign a permanent replacement for the post once it has found the right candidate through its nationwide search.
Prior to her appointment, Nash was serving as BBW’s chairman is said to be a seasoned investment banking veteran. In any case, she will assume the role of interim CEO when Meslow leaves on May 12.
“It has been an honor and a privilege to lead this great company as CEO and be a part of the organization for nearly two decades,” Andrew Meslow said in a press release. “After much consideration and many discussions with my family, I have decided to step down as CEO so that I can focus on my health. As difficult as this decision was, I know I will be leaving this amazing company in highly capable hands with Sarah’s oversight, the deep and experienced bench of leadership and the most talented associates in the industry.”
Meslow went on to say, “Thanks to the hard work and dedication of a team that is second to none, Bath & Body Works has achieved incredible results. I am proud of what the Bath & Body Works team has accomplished and am confident in its bright future.”
Meanwhile, Market Watch reported that shares of Bath & Body Works slid after it was announced that Meslow is vacating his post. The shares reportedly plummet 3.2% after hours to $48.70.


Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Bernstein Raises 2026 Nickel Price Forecast as Indonesia Tightens Supply
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Dollar Slips as Oil Prices Ease, Fed Rate Outlook Remains Uncertain
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Gordie Howe Bridge to Open July 27 After U.S.-Canada Reach Toll Revenue Agreement
Gold Prices Slip as U.S.-Iran Conflict, Fed Rate Hike Bets Pressure Precious Metals
Dollar Ends Week Higher as Yen Jumps on Japan Pension Fund Investment Plans
Japan Wholesale Inflation Jumps as Energy Shock Drives Import Costs Higher
European Regulators Clash With U.S. Treasury Over Private Credit Transparency
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
Asian Stocks Slip as Iran Tensions, Samsung Weakness and Fed Caution Weigh on Markets
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
US Back-to-School Spending Seen Falling as Families Focus on Essentials 



